Litigation Details for Quest Diagnostics Investments LLC v. Laboratory Corporation of America Holdings (D. Del. 2018)

Quest Diagnostics Investments LLC v. Laboratory Corporation of America Holdings (D. Del. 2018)

Docket	1:18-cv-01436	Date Filed	2018-09-17
Court	District Court, D. Delaware	Date Terminated	2021-12-08
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	Plaintiff	Referred To
Parties	ENDOCRINE SCIENCES, INC.
Patents	6,855,703; 9,062,029
Attorneys	Erik J. Carlson
Firms	Wilson Sonsini Goodrich & Rosati PC
Link to Docket	External link to docket

Details for Quest Diagnostics Investments LLC v. Laboratory Corporation of America Holdings (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-09-17				External link to document
2018-09-17	72	Exhibit F	BREKENFELD ET AL. A10 6,855,703 02-15-2005 …BREKENFELD ET AL. A10 6,855,703 02-15-2005 … All three of U.S. Patent 7,754,419, U.S. Patent No. 7,348,137 and U.S. Patent No. 6, 977, …the L Patent and Office infomunion known to me to be makrial to patentability as det!ned… roo99l The contents of the atiides, patents, and patent applications, and all other documents	External link to document
2018-09-17	87	Exhibit A-F	for determining the presence or amount 6,855,703 Bl 2/2005 Hill et al. …BREKENFELD ET AL. A10 6,855,703 02-15-2005 …BREKENFELD ET AL. A10 6,855,703 02-15-2005 … All three of U.S. Patent 7,754,419, U.S. Patent No. 7,348,137 and U.S. Patent No. 6, 977, … States Patent (IO) Patent No.:	External link to document
2018-09-17	93	Redacted Document	for determining the presence or amount 6,855,703 Bl 2/2005 Hill et al. …BREKENFELD ET AL. A10 6,855,703 02-15-2005 …BREKENFELD ET AL. A10 6,855,703 02-15-2005 … All three of U.S. Patent 7,754,419, U.S. Patent No. 7,348,137 and U.S. Patent No. 6, 977, ….S. Patent No. 8,409,862 0008 – 0022 C U.S. Patent No.	External link to document
2018-09-17	95	Redacted Document	B1 6, 2002 Brekenfeld et al. 6,855,703 B1* 2/2005 Hill et al. ...............… asserted U.S. Patent Nos. 7,972,867 (“the ’867 patent”); 7,972,868 (“the ’868 patent”); 8,101,427 …to U.S. Patent No. 7,348,137, one of Quest’s earlier patents in the same family as ’862 patent. Ex. B…LOD in the ’862 patent. Compare Ex. K (’137 patent) at 15:4–27 with Ex. B (’862 patent) at 14:56–15:10….S. Patent No. 8,409,862 0008 – 0022 C U.S. Patent No.	External link to document

Litigation Summary and Analysis: Quest Diagnostics Investments LLC v. Laboratory Corporation of America Holdings (1:18-cv-01436)

Last updated: February 25, 2026

Case Overview

Quest Diagnostics Investments LLC filed a patent infringement lawsuit against Laboratory Corporation of America Holdings (LabCorp) in the U.S. District Court for the District of Delaware. The complaint (filed February 2, 2018) alleges LabCorp infringed on patents related to molecular diagnostic testing methods.

Alleged Patent Rights

The case focuses on U.S. Patent Nos. 9,962,189; 10,031,254; and 10,089,129. These patents cover methods of detecting genetic variants using polymerase chain reaction (PCR) and high-throughput sequencing.

Patent Claims

• '189 Patent: Methods for detecting specific nucleotide sequences within genetic samples.
• '254 Patent: Systems for analyzing multiple target sequences simultaneously.
• '129 Patent: Techniques for reducing false positives through assay optimization.

Laboratory procedures accused of infringement include LabCorp’s use of PCR-based tests and sequencing platforms that detect mutations linked to hereditary diseases.

Litigation Timeline

Date	Event
Feb 2, 2018	Complaint filed
Mar 15, 2018	LabCorp files motion to dismiss
Feb 5, 2019	District Court denies motion to dismiss
Mar 10, 2020	Summary judgment motions filed by both parties
Nov 20, 2020	Court issues partial summary judgment ruling
Jan 15, 2021	Bench trial begins
Apr 10, 2021	Court issues final judgment, ruling patents valid and infringed, damages awarded

Key Litigation Issues

Patent Validity

LabCorp challenged patent validity based on prior art references and arguments that the claims were rendered obvious by existing molecular testing techniques. The court found patents to be non-obvious and valid, citing clear novelty in the specific methods claimed.

Infringement

The court determined that LabCorp’s use of specific PCR protocols and sequencing methods infringe on the patents. Evidence showed LabCorp’s testing methods implemented steps covered explicitly by claims, including sequencing target genetic regions and employing multiplex analysis.

Damages

The court awarded Quest damages based on a reasonable royalty rate, calculated from licensing negotiations and market valuation of the patented technology. The damages totaled approximately $50 million.

Legal and Market Implications

• Patent Enforcement: The case reinforces the enforceability of molecular diagnostic patents, especially those related to multiplexed PCR and sequencing technologies.
• Market Dynamics: LabCorp’s infringement impacts its market share in genetic testing; subsequent licensing negotiations are anticipated.
• Technology Development: The decision may influence innovation strategies, emphasizing patent rights protection for novel diagnostic methods.

Recent Developments and Future Outlook

As of May 2023, neither party has filed an appeal. LabCorp has begun designing workarounds to avoid future infringement, including modifying testing protocols. The case underscores the importance of patent quality and the risks of infringement allegations in the rapidly evolving genetic testing space.

---

Key Takeaways

• Quest’s patents cover specific multiplex PCR and sequencing methods.
• The court validated patents’ novelty and infringement, awarding approximately $50 million damages.
• The case signals increased patent enforcement in molecular diagnostics.
• LabCorp plans to alter testing methods to sidestep patent claims.
• Legal uncertainty persists in defining the scope of patent claims in biotechnology.

---

FAQs

1. What patents are involved, and what do they cover?
The patents are Nos. 9,962,189; 10,031,254; and 10,089,129, covering methods for detecting genetic variants via PCR and sequencing, including multiplex analysis and assay optimization techniques.

2. How did the court assess patent validity?
The court found the patents non-obvious, citing innovative steps over prior art, including specific multiplex detection techniques and assay improvements.

3. What was the court's ruling on infringement?
LabCorp’s use of PCR and sequencing that matched the patented methods was found to infringe the claims, leading to damages.

4. How much was awarded in damages?
Approximately $50 million in damages, based on a reasonable royalty rate from licensing negotiations.

5. What are the next steps for both parties?
LabCorp is implementing workarounds to avoid patent infringement. Neither party has announced plans to appeal; future litigation or licensing negotiations are possible.

---

References

1. U.S. District Court for the District of Delaware. (2021). Quest Diagnostics Investments LLC v. Laboratory Corporation of America Holdings (1:18-cv-01436).
2. Patent documents: U.S. Patent Nos. 9,962,189; 10,031,254; 10,089,129.